Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
23MB
[thumbnail of Supporting Information]
Preview
PDF (Supporting Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
523kB

Item Type:Review
Title:Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling
Creators Name:Rüdebusch, J., Benkner, A., Nath, N., Fleuch, L., Kaderali, L., Grube, K., Klingel, K., Eckstein, G., Meitinger, T., Fielitz, J. and Felix, S.B.
Abstract:BACKGROUND AND PURPOSE: Heart failure (HF) is associated with an impaired NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway, and its augmentation is thought to be beneficial in HF therapy. We hypothesized that stimulation of sGC by the sGC stimulator riociguat (Rio) prevents pathological cardiac remodelling and HF in response to chronic pressure overload. EXPERIMENTAL APPROACH: Transverse aortic constriction (TAC) or sham surgery was performed in C57BL/6N mice. After 3 weeks of TAC when HF was established, animals were randomized to receive either riociguat (Rio) or its solvent (Sol) for 5 additional weeks. Cardiac function was evaluated weekly by echocardiography. Eight weeks after surgery, histological analyses were performed to evaluate remodelling and the transcriptome of the left ventricles (LV) was analysed by RNA Sequencing. Cell culture experiments were used for mechanistically studies. KEY RESULTS: TAC resulted in a continuous decrease of LV ejection fraction (LVEF from 56.6±2.2 to 32.0±4.1%) and an increase in LV mass (LVM/BW from 3.7±0.2 to 6.1±0.3 mg/g) until week 3. Five weeks of riociguat treatment resulted in an improved LVEF (TAC+Rio 43.4±6.0% vs. TAC+Sol 20.9±4.3%; p<0.001) and a decrease in LVM/BW (5.5±0.4 mg/g vs.7.7±0.7 mg/g; p<0.001), myocardial fibrosis and myocyte cross-sectional area. RNA sequencing revealed that riociguat reduced the expression of myocardial stress and remodelling genes (e.g. Nppa, Nppb, Myh7, collagen) and attenuated the activation of biological pathways associated with cardiac hypertrophy and HF. Riociguat reversed pathological stress response in cultivated myocytes and fibroblasts. CONCLUSION AND IMPLICATION: Stimulation of the sGC reverses TAC-induced HF and remodelling, which is associated with improved myocardial gene expression.
Keywords:Heart Failure, Soluble Guanylate Cyclase, cGMP Signalling, Riociguat, TAC, RNA Sequencing, Animals, Mice
Source:British Journal of Pharmacology
ISSN:0007-1188
Publisher:Wiley
Volume:179
Number:11
Page Range:2430-2442
Date:June 2020
Official Publication:https://doi.org/10.1111/bph.15333
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library